Treatment Guidelines for Stage 3B ER+ HER2- Breast Cancer

Overview of Treatment Approach

• For stage 3B ER-positive, HER2-negative breast cancer, neoadjuvant chemotherapy followed by surgery, radiation therapy (if indicated), and adjuvant endocrine therapy is the standard approach, with consideration of adjuvant CDK4/6 inhibitors or olaparib in high-risk patients 1

Neoadjuvant Systemic Therapy

• Anthracycline-taxane sequential regimens are the standard backbone for neoadjuvant chemotherapy in stage 3B disease 1
• Typical regimens include doxorubicin/cyclophosphamide followed by a taxane (paclitaxel or docetaxel) for 12-24 weeks total 1
• Dose-dense schedules with growth factor support should be considered given their documented benefit over conventional schedules 1

Radiation Therapy

• Postmastectomy radiation is indicated for stage 3B disease due to locally advanced presentation 2
• Radiation should be given after completion of all chemotherapy 2
• Endocrine therapy can be administered concurrently with radiation 2

Adjuvant Endocrine Therapy

• All patients with ER-positive disease must receive adjuvant endocrine therapy for 5-10 years 1
• For premenopausal patients, ovarian suppression (LHRH agonist) plus aromatase inhibitor is preferred for high-risk disease 3
• For postmenopausal patients, aromatase inhibitors (anastrozole, letrozole, or exemestane) are the preferred initial endocrine therapy 3

Risk-Based Adjuvant Intensification

• For patients with residual high-risk disease after neoadjuvant chemotherapy or multiple positive lymph nodes after primary surgery, adjuvant abemaciclib (150 mg twice daily for 2 years) combined with endocrine therapy should be strongly considered 1
• For patients with germinal BRCA1/2 mutations and high-risk features (multiple positive nodes or residual disease after neoadjuvant therapy), adjuvant olaparib for 1 year should be offered 1

Critical Considerations

• Ensure cardiac monitoring before and during chemotherapy, particularly with anthracycline-containing regimens 4
• Do not give endocrine therapy concurrently with chemotherapy—they must be sequential with endocrine therapy starting after chemotherapy completion 2
• Do not omit adjuvant endocrine therapy even if pathological complete response is achieved, as ER-positive disease requires hormonal suppression 1